Progress towards therapies for disease modification in Parkinson's disease

Nirosen Vijiaratnam, Tanya Simuni, Oliver Bandmann, Huw R. Morris, Thomas Foltynie*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

The development of interventions to slow or halt the progression of Parkinson's disease remains a priority for patients and researchers alike. To date, no agents have been shown to have unequivocal evidence of disease-modifying effects in Parkinson's disease. The absence of disease-modifying treatments might relate not only to inadequate approaches for the selection of therapeutic candidates but also to insufficient attention to detail in clinical trial design. Better understanding of Parkinson's disease pathogenesis associated with advances in laboratory models, the use of objective biomarkers of disease progression and target engagement, and a focus on agents known to be safe for human use, alongside the use of precision medicine approaches, should together greatly increase the likelihood for successful identification of disease-modifying treatments for Parkinson's disease.

Original languageEnglish (US)
Pages (from-to)559-572
Number of pages14
JournalThe Lancet Neurology
Volume20
Issue number7
DOIs
StatePublished - Jul 2021

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Progress towards therapies for disease modification in Parkinson's disease'. Together they form a unique fingerprint.

Cite this